삼아제약

009300KOSDAQ의약품 제조업

57.0 / 100

Reference Date: 2026-04-13

Financial Score27.5 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Samah Pharmaceutical is a pharmaceutical company specializing in the production and sale of respiratory, dermatological, and analgesic drugs, along with health functional foods. It operates a state-of-the-art production facility established in 2009 at the Munmak plant. However, revenue declined by 18.6% year-on-year in 2023 due to a decrease in respiratory patients, with respiratory drugs (67.7%) and analgesics (13.2%) contributing the majority of sales.

Number of Employees

310people

Average Salary

56.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.50Industry Average 14.806.5Point

Lower than industry avg (good)

PBR

0.44Industry Average 1.047.0Point

Half of industry avg (excellent)

ROE

5.78Industry Average 4.424.0Point

In line with industry avg

Debt Ratio

2.21Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼10.1% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼25.5% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 9.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 15,890Won52-week high 19,05052-week low 15,070

1-month return3.0Point

1m 0.38% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral[기재정정]정기주주총회결과2026-03-30
Neutral정기주주총회결과2026-03-27
Neutral기업가치제고계획(자율공시)2026-03-27
Neutral사업보고서 (2025.12)2026-03-20
Neutral감사보고서제출2026-03-19